192 related articles for article (PubMed ID: 21152296)
1. Molecular modeling studies of 4,5-dihydro-1H-pyrazolo[4,3-h] quinazoline derivatives as potent CDK2/Cyclin a inhibitors using 3D-QSAR and docking.
Ai Y; Wang ST; Sun PH; Song FJ
Int J Mol Sci; 2010 Sep; 11(10):3705-24. PubMed ID: 21152296
[TBL] [Abstract][Full Text] [Related]
2. 3D-QSAR and docking studies on pyrazolo[4,3-h]qinazoline-3-carboxamides as cyclin-dependent kinase 2 (CDK2) inhibitors.
Lan P; Chen WN; Xiao GK; Sun PH; Chen WM
Bioorg Med Chem Lett; 2010 Nov; 20(22):6764-72. PubMed ID: 20869873
[TBL] [Abstract][Full Text] [Related]
3. Molecular Modeling and Design Studies of Purine Derivatives as Novel CDK2 Inhibitors.
Zhang G; Ren Y
Molecules; 2018 Nov; 23(11):. PubMed ID: 30423939
[TBL] [Abstract][Full Text] [Related]
4. 3D-QSAR CoMFA and CoMSIA study on benzodipyrazoles as cyclin dependent kinase 2 inhibitors.
Dessalew N; Singh SK
Med Chem; 2008 Jul; 4(4):313-21. PubMed ID: 18673142
[TBL] [Abstract][Full Text] [Related]
5. Molecular modeling studies to characterize N-phenylpyrimidin-2-amine selectivity for CDK2 and CDK4 through 3D-QSAR and molecular dynamics simulations.
Chohan TA; Chen JJ; Qian HY; Pan YL; Chen JZ
Mol Biosyst; 2016 Apr; 12(4):1250-68. PubMed ID: 26883408
[TBL] [Abstract][Full Text] [Related]
6. Combined 3D-QSAR modeling and molecular docking studies on pyrrole-indolin-2-ones as Aurora A kinase inhibitors.
Ai Y; Wang ST; Sun PH; Song FJ
Int J Mol Sci; 2011; 12(3):1605-24. PubMed ID: 21673910
[TBL] [Abstract][Full Text] [Related]
7. An in silico exploration of the interaction mechanism of pyrazolo[1,5-a]pyrimidine type CDK2 inhibitors.
Li Y; Gao W; Li F; Wang J; Zhang J; Yang Y; Zhang S; Yang L
Mol Biosyst; 2013 Sep; 9(9):2266-81. PubMed ID: 23864105
[TBL] [Abstract][Full Text] [Related]
8. Molecular docking and MD simulation studies of 4-thiazol-N-(pyridin-2-yl)pyrimidin-2-amine derivatives as novel inhibitors targeted to CDK2/4/6.
Liang JD; Zhang YE; Qin F; Chen WN; Jiang WM; Fang Z; Liang XL; Zhang Q; Li J
J Cancer Res Clin Oncol; 2024 Jun; 150(6):302. PubMed ID: 38856753
[TBL] [Abstract][Full Text] [Related]
9. Combined pharmacophore modeling, docking, and 3D-QSAR studies of PLK1 inhibitors.
Lu S; Liu HC; Chen YD; Yuan HL; Sun SL; Gao YP; Yang P; Zhang L; Lu T
Int J Mol Sci; 2011; 12(12):8713-39. PubMed ID: 22272100
[TBL] [Abstract][Full Text] [Related]
10. Docking and 3D-QSAR modeling of cyclin-dependent kinase 5/p25 inhibitors.
Ul Haq Z; Uddin R; Wai LK; Wadood A; Lajis NH
J Mol Model; 2011 May; 17(5):1149-61. PubMed ID: 20686908
[TBL] [Abstract][Full Text] [Related]
11. Mapping the binding site of a large set of quinazoline type EGF-R inhibitors using molecular field analyses and molecular docking studies.
Hou T; Zhu L; Chen L; Xu X
J Chem Inf Comput Sci; 2003; 43(1):273-87. PubMed ID: 12546563
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of novel 5,6-dihydropyrimido[4,5-f]quinazoline derivatives as potent CDK2 inhibitors.
Hu X; Zhao H; Wang Y; Liu Z; Feng B; Tang C
Bioorg Med Chem Lett; 2018 Nov; 28(20):3385-3390. PubMed ID: 30197029
[TBL] [Abstract][Full Text] [Related]
13. 3D-QSAR, molecular dynamics simulations, and molecular docking studies on pyridoaminotropanes and tetrahydroquinazoline as mTOR inhibitors.
Chaube U; Bhatt H
Mol Divers; 2017 Aug; 21(3):741-759. PubMed ID: 28577112
[TBL] [Abstract][Full Text] [Related]
14. Insight into the interactions between novel isoquinolin-1,3-dione derivatives and cyclin-dependent kinase 4 combining QSAR and molecular docking.
Zheng J; Kong H; Wilson JM; Guo J; Chang Y; Yang M; Xiao G; Sun P
PLoS One; 2014; 9(4):e93704. PubMed ID: 24722522
[TBL] [Abstract][Full Text] [Related]
15. 3D-QSAR and molecular docking studies on derivatives of MK-0457, GSK1070916 and SNS-314 as inhibitors against Aurora B kinase.
Zhang B; Li Y; Zhang H; Ai C
Int J Mol Sci; 2010 Nov; 11(11):4326-47. PubMed ID: 21151441
[TBL] [Abstract][Full Text] [Related]
16. 3D-QSAR and molecular docking studies on fused pyrazoles as p38α mitogen-activated protein kinase inhibitors.
Lan P; Huang ZJ; Sun JR; Chen WM
Int J Mol Sci; 2010 Sep; 11(9):3357-74. PubMed ID: 20957100
[TBL] [Abstract][Full Text] [Related]
17. In silico design novel (5-imidazol-2-yl-4-phenylpyrimidin-2-yl)[2-(2-pyridylamino)ethyl]amine derivatives as inhibitors for glycogen synthase kinase 3 based on 3D-QSAR, molecular docking and molecular dynamics simulation.
He Q; Han C; Li G; Guo H; Wang Y; Hu Y; Lin Z; Wang Y
Comput Biol Chem; 2020 Oct; 88():107328. PubMed ID: 32688011
[TBL] [Abstract][Full Text] [Related]
18. Design of Novel Chemotherapeutic Agents Targeting Checkpoint Kinase 1 Using 3D-QSAR Modeling and Molecular Docking Methods.
Balupuri A; Balasubramanian PK; Cho SJ
Curr Comput Aided Drug Des; 2016; 12(4):302-313. PubMed ID: 27585602
[TBL] [Abstract][Full Text] [Related]
19. 3D-QSAR and molecular docking study of LRRK2 kinase inhibitors by CoMFA and CoMSIA methods.
Pourbasheer E; Aalizadeh R
SAR QSAR Environ Res; 2016 May; 27(5):385-407. PubMed ID: 27228480
[TBL] [Abstract][Full Text] [Related]
20. Identification of the Structural Features of Guanine Derivatives as MGMT Inhibitors Using 3D-QSAR Modeling Combined with Molecular Docking.
Sun G; Fan T; Zhang N; Ren T; Zhao L; Zhong R
Molecules; 2016 Jun; 21(7):. PubMed ID: 27347909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
